Clinical Trials Logo

Clinical Trial Summary

Our previous work on the use of probiotics improved the clinical symptoms in irritable bowel syndrome with constipation-predominant. This study would like to explore further use of probiotics in the immune system of the patients with irritable bowel syndrome.


Clinical Trial Description

This is a case control study involving participants who fulfilled the Rome III criteria for constipation-predominant irritable bowel syndrome. The patients were recruited from the Gastroenterology clinic at Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur. A total of 165 participants were recruited based on probability (power) of 0.8 and Type I error was set at 0.05. The investigators included healthy participants above 18 years old. Those less than 18 years old; constipation due to other medical illnesses such as diabetes mellitus, inflammatory bowel disease, hypothyroidism, colorectal cancer, neurological diseases, major depression, lactose intolerance, pregnancy, breastfeeding women and must not be on chronic opioids or anti- depressants were excluded. Participants must not consume any antibiotics, probiotic, prebiotic, symbiotic and/or laxatives less than two weeks before recruitment. Participants were required to consume three bottles of 125 ml cultured milk drink daily for 30 days. Each bottle contains 10^9 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose. Cold chain was maintained below 10°C during storage, transportation and distribution. Prior to consumption of the cultured milk drinks, fecal and blood samples from the participants were obtained to determine their baseline fecal pH and serum cytokines level respectively. Each of the participants answered a food frequency questionnaire to assess their dietary profile (data are not presented in this paper) and the Garrigues Questionnaire to evaluate their clinical symptoms and physical activity. The same parameters were taken following 30 days of cultured milk drinks' consumption. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04647045
Study type Interventional
Source National University of Malaysia
Contact
Status Completed
Phase N/A
Start date May 2, 2017
Completion date August 1, 2018

See also
  Status Clinical Trial Phase
Completed NCT00730171 - An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT00215566 - A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c Phase 2
Completed NCT00765999 - An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT02559206 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Recruiting NCT05646186 - Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome N/A
Completed NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Recruiting NCT05519683 - Home Transcutaneous Electrical Acustimulation (TEA) Phase 2/Phase 3
Active, not recruiting NCT04166058 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase 3
Completed NCT05164861 - Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations N/A
Completed NCT04968652 - IBS-C Questionnaire Study
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Terminated NCT02559817 - A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation Phase 2
Recruiting NCT05796388 - A Study of Virtual Reality and Linaclotide for IBS-C N/A
Completed NCT00380250 - Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04214470 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Not yet recruiting NCT06219707 - Electro-acupuncture for Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT03596905 - Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Completed NCT04132804 - Effect of Tai Chi as Treatment for IBS-C N/A
Completed NCT00938717 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 3